Our pipeline of SPEARs™ targets transcription factors and regulatory pathways of disease that make cells cancerous or dampen the immune system against tumors
| Program/Target | Indication(s)/Settings | Discovery | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| ST101 C/EBPβ | ST101-101 Phase 1/2 Study | |||||
| ST101 C/EBPβ | Phase 2: Dose Expansion | |||||
| ST101 C/EBPβ | rGBM Main Study †* | |||||
| ST101 C/EBPβ | rGBM Window-of-Opportunity Sub-Study †* | |||||
| ST101 C/EBPβ | ndGBM Window-of-Opportunity Sub-Study * (ComboTx) | |||||
| ST316 β-catenin (Wnt pathway) |
Colorectal Cancer | |||||
| JunAP cJun (AP1 complex) | Solid and heme | |||||
| FoxAP FOXP3 | Solid and heme (ComboTx) | |||||
| ST101 C/EBPβ |
| ST101-101 Phase 1/2 Study |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| Phase 2: Dose Expansion |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| rGBM Main Study †* |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| rGBM Window-of-Opportunity Sub-Study †* |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| ndGBM Window-of-Opportunity Sub-Study * (ComboTx) |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST316 β-catenin (Wnt pathway) |
| Colorectal Cancer |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| JunAP cJun (AP1 complex) |
| Solid and heme |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| FoxAP FOXP3 |
| Solid and heme (ComboTx) |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| Program/Target | Indication(s)/Settings | Discovery | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|
†FDA Fast Track Designantion *FDA Orphan Drug Designation